Metastatic castration-resistant prostate cancer that has become resistant to docetaxel chemotherapy represents one of the greatest clinical challenges in the management of this disease.
Tomasz M. Beer, MD
Here we review current therapies for nonmetastatic CRPC and discuss the recently completed and ongoing trials for this emerging disease state.
The 2015 ASCO Annual Meeting delivered new practice-changing results in the area of prostate cancer.
Here we discuss the efficacy and safety of zoledronic acid, denosumab, enzalutamide, abiraterone, and radium-223 and review the available data regarding the cost of denosumab compared with that of zoledronic acid.
We need to understand each patient’s cancer and its microenvironment well enough to develop targeted treatments that will kill the tumor the first time—for if we let it escape, 70 years of prostate cancer research teaches us that our job will only get harder.
Two experts discuss newly available and upcoming treatment options, such as abiraterone and MDV3100, for patients with castration-resistant prostate cancer.